Stock Selection: Claude Opus 5's picks for 2026-09-17
Claude Opus 5 picked SMH, QQQ, XLV, XLK, XLE for a 1-day horizon. Portfolio return vs SPY: +0.47%. Picks that beat SPY: 80%.
| Experiment | Stock Selection |
|---|---|
| Model | Claude Opus 5 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-17 |
| Measured to | 2026-09-18 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +0.47% |
| Picks that beat SPY | 80% |
| Benchmark return | -0.20% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | SMH | +0.71% | 57% | +0.91% | Yes |
| 2 | QQQ | +0.35% | 55% | +0.55% | Yes |
| 3 | XLV | -0.41% | 53% | -0.21% | No |
| 4 | XLK | +0.24% | 52% | +0.44% | Yes |
| 5 | XLE | +0.47% | 49% | +0.67% | Yes |
The model's market view
The event resolved hawkishly and the rotation it produced is the basis for this basket. The FOMC raised rates 25 basis points to 3.75%-4.00% on 16 September in a unanimous 12-0 vote, the first hike since 2023. The dot plot was firmly hawkish: 16 of 18 officials see at least one more hike this year, four pencilled in two more, the median projected rate stays near 4.1% through end-2027 with no cuts in 2027, and the return to 2% core inflation is now pushed out to 2029, with Chair Warsh again declining to submit his own dot (vantagemarkets.com/market-news/key-takeaways-fed-decision-september-2026-september-17-2026/, fool.com). Warsh's phrase about supporting a timelier return to the 2% goal is what turned the tape. Critically, the damage was not evenly distributed: the Dow lost 631.21 points or 1.21% to 51,461.90 with Goldman Sachs leading it lower, the S&P 500 fell 0.45% to 7,551.81, but the Nasdaq Composite finished essentially flat at 25,978.42, down 0.01% (cnbc.com/2026/09/15/stock-market-today-live-updates.html). That dispersion is the signal. In a confirmed higher-for-longer regime with the 10-year above 5%, the market is treating net-cash, self-funding mega-cap technology as the defensive asset and selling financials and cyclicals that carry credit and demand risk. Overnight, Bloomberg reported Treasuries paring losses and equity futures climbing as Warsh's resolve reassured markets, with the 2-year easing one basis point to 4.72%. I am therefore reversing the energy-and-defensives tilt I would previously have run, and I want to be explicit about why: XLE is quoted at $63.53 today against $65.14 on 11 September even as crude held above $100, so energy equities are falling while the commodity rises, and 24/7 Wall St. reports futures traders positioning for a 12% drop in energy stocks over the next month. That is the market pricing demand destruction, not margin expansion. Semiconductors are doing the opposite, with SMH recovering from $541.50 on 14 September to $551.47 on 16 September. Ranks 1, 2 and 5 are three expressions of the same growth-over-value theme, which is a deliberate concentration on the observed post-FOMC rotation rather than an accident of selection; ranks 3 and 4 are the hedges against it. The obvious risk is that this reverses: if the hawkish dots are digested over days rather than hours, long-duration growth is exactly what gets repriced next, and I would be positioned on the wrong side of it.
Why each pick
SMH
Thesis: the cleanest expression of the rotation the Fed decision confirmed, and the only pick here with a verified recovery trend. SMH traded between $547.51 and $553.12 on 16 September and stood at $551.47, up from $541.50 on 14 September, so the group has recovered roughly 1.8% from Monday's AI-pacing shock that knocked the PHLX Semiconductor Index down 5.9%. That catalyst was an opinion essay on the pace of frontier model development, publicly dismissed by President Trump on competitiveness grounds, not a change to orders or guidance. With the Nasdaq Composite finishing Wednesday flat against a 1.21% Dow decline, the market demonstrated it will fund a hawkish Fed by selling cyclicals and financials rather than large-cap technology. SMH concentrates about a fifth of its weight in Nvidia, giving roughly twice SPY's sensitivity to the names leading that. Risks: semiconductors are the longest-duration equity exposure in the market, so if the 10-year pushes further above 5% this leg suffers most. Morgan Stanley has flagged weakening DRAM demand with building inventory and NAND oversupply, and SOXX saw $393 million of outflows in the week to 7 September including $259 million in a single session. Price note: this is the most recent regular-session quote I could verify, from 16 September, not an intraday print for today. Source: robinhood.com/us/en/stocks/SMH/, www.cnbc.com/2026/09/15/stock-market-today-live-updates.html
QQQ
Thesis: the broad, lower-variance version of rank 1, and a direct structural bet against SPY's composition. SPY carries roughly a third of its weight outside technology in financials, industrials, staples and healthcare, and Wednesday showed precisely that portion taking the damage, with Goldman Sachs leading the Dow's 631-point drop while the Nasdaq Composite closed flat. The logic is coherent rather than merely momentum-based: with the dot plot signalling no cuts in 2027 and a median rate near 4.1%, the companies that outperform are the ones that do not need to refinance, and the Nasdaq-100's largest constituents are net-cash balance sheets with pricing power. Bloomberg's overnight report of futures climbing and Treasuries paring losses suggests that read is being extended rather than reversed. Risks: this is the same theme as rank 1 and duplicates much of its exposure, so the basket is less diversified than five names imply. If the hawkish projections are digested over days rather than hours, long-duration growth is the natural next thing to be repriced. Price note: I could not retrieve a current QQQ quote from a source I trust; the pages I reached returned either stale cached sessions from earlier in 2026 or no price at all, so I am omitting reference_price rather than restating a close from memory. Source: www.cnbc.com/2026/09/15/stock-market-today-live-updates.html, www.bloomberg.com/news/articles/2026-09-16/stock-market-today-dow-s-p-live-updates
XLV
Thesis: the hedge against the growth legs, and the one pick that works if the hawkish dots get digested slowly and long-duration assets are sold over the coming sessions. Health care carries a beta near 0.8, no AI capex exposure, negligible crude input sensitivity, and near-term contractual cash flows rather than bond-proxy duration, which matters now that the Fed has formally projected no cuts in 2027 and a delayed return to 2% inflation until 2029. State Street Investment Management upgraded healthcare from neutral to positive in its Q3 2026 sector outlook after nearly a year of caution, which is a genuine change of stance rather than a restatement. Risks: I want to flag the contrary technical evidence directly, because it is recent. Stock Analysis commentary notes XLV is testing key support after breaking below a major trendline, which cuts against the position. XLV is also roughly a 10% weight inside SPY, so even a correct call yields modest relative outperformance. Drug-pricing and policy headlines remain an unforecastable single-session risk. Price note: I could not verify a current XLV quote at the moment of answering, so reference_price is omitted rather than invented. Source: stockanalysis.com/etf/xlv/, stockanalysis.com/etf/xle/
XLK
Thesis: the third expression of the growth-over-value rotation, chosen over a fourth energy or cyclical name because the evidence for the rotation is stronger than the evidence for anything else available today. XLK holds 76 S&P 500 technology constituents against SMH's 26 semiconductor names, so it captures the software and services side that is not exposed to the memory cycle or to chip-specific inventory risk, while still benefiting from the same flight into self-funding balance sheets. TipRanks-sourced commentary rates XLK a Strong Buy on a weighted average of analyst ratings alongside QQQM and SMH, and the fund returned 36.37% over the past year. Risks: this triples down on a theme already carried by ranks 1 and 2, and I would rather say so plainly than present the basket as diversified. XLK is 99.08% technology by sector weight, so there is no internal offset if the rotation reverses, and it is the sector most directly exposed to further increases in the long end. Price note: the only XLK quote page I could reach returned a cached session from 3 April 2026, which would be misleading to report as current, so reference_price is omitted. Source: stockanalysis.com/etf/xlk/, www.robinhood.com/us/en/stocks/XLK/
XLE
Thesis, stated with a downgrade I think the evidence forces. I have carried energy as a top-ranked pick repeatedly this week on the logic that crude above $100 and the Saudi East-West pipeline closure would flow into producer earnings. The price data says that has not been working: XLE is quoted at $63.53 today with a session range of $63.45 to $64.15, against $65.14 at the close on 11 September, so the fund has fallen about 2.5% while crude rose. Worse, 24/7 Wall St. reports futures traders betting on a 12% drop in energy stocks over the next month, and Interactive Brokers' senior economist has been discussing the oil price that breaks the American consumer. That is the market pricing demand destruction. I keep the position at the bottom of the ranking only because it is the one genuine inflation hedge in a basket otherwise concentrated in long-duration growth, and because the Fed has now formally projected inflation above target until 2029, with energy having been the best-performing sector of 2026 and XLE up 7.4% in August alone. Risks: the options positioning above is the clearest contrary signal in this entire basket, XLE sits below its $66.17 52-week high and is making lower highs, and any Hormuz de-escalation would compress the premium quickly. Price note: this is a live intraday quote for 17 September. Source: robinhood.com/us/en/stocks/XLE/, stockanalysis.com/etf/xle/
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| GPT-5.6 Sol | GNRC, VICR, NBIS, AMD, IREN | +0.59% | 60% |
| Muse Spark 1.1 | XLF, JPM, XLE, BAC, OXY | +0.14% | 60% |
| Grok 4.5 | NVDA, TSLA, SMH, AMD, QQQ | +0.65% | 80% |
| Claude Sonnet 4.5 | GNRC, NBIS, ARM, MU, COHR | -0.38% | 60% |
| DeepSeek V3 | GNRC, NBIS, ARM, MU, COHR | -0.38% | 60% |
Written up on ForecastNest Insights: Stock Selection: Claude Opus 5's picks for 2026-09-17.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.